translational medicine Archives - ELIAS Animal Health

ELIAS Animal Health to Present New Research at Upcoming Human and Veterinary Oncology Conferences

LENEXA, Kan., September 4, 2025 -- ELIAS Animal Health, a leader in advancing innovative therapies for veterinary oncology, today announced that it will present promising new research on its novel chemo-immunotherapy approach for canine osteosarcoma at two upcoming scientific meetings in September 2025. 18th American Association for Cancer Research (AACR) Conference on The Science of Cancer Health Disparities, being held September 18–21, 2025, in Baltimore, Md. The presentation will highlight the safety and efficacy of integrating traditional cytotoxic chemotherapy with a vaccine-enhanced adoptive cell therapy in canine osteosarcoma, a well-known translational model for pediatric osteosarcoma in humans. 2025 Veterinary Cancer Society Annual Conference, being held September 25–27, 2025, in Salt Lake City, Utah. The company’s findings will be shared in an oral presentation at the Research Spotlight Symposium on September 26, 2025. The presentation will focus on the clinical experience using this combination therapeutic strategy with its USDA-approved cancer immunotherapy [...]

jwiley2025-09-04T06:25:17-06:00September 4th, 2025|

Pet Cancer Awareness Month and the One Health Connection

Pets bring us immense joy and companionship, making them cherished members of our families. However, just like humans, they too can be affected by cancer. Pet Cancer Awareness Month, observed throughout November, is a reminder of the importance of early detection, prevention, and treatment of cancer in our animal companions. Fittingly, it coincides with One Health Day on November 3, which emphasizes the interconnectedness of human and animal health, and the environment we share. Cancer Can Happen to Pets Too Cancer is a complex and devastating disease that can affect any breed, age, or species of pet. Just like in humans, pet cancer occurs when abnormal cells grow uncontrollably, forming tumors that can spread to other parts of the body. The most common types of cancer found in dogs include lymphoma, mast cell tumors, and osteosarcoma (bone cancer), while cats are often prone to lymphoma, mammary cancer, and oral cancers. [...]

jwiley2023-10-31T12:32:43-06:00October 31st, 2023|

Oncolytic Virotherapy in Veterinary Medicine

ELIAS Animal Health previously announced it has in-licensed an oncolytic vaccinia virus treatment for pet animals from Genelux Corporation. The agreement grants ELIAS the worldwide right to development and commercialization of V-VET1 for the diagnosis, prevention and treatment of cancer in veterinary medicine. Check out some of the most frequently asked questions about this agreement and what we plan to do with the technology. What is V-VET1? V-VET1 is Genelux Corporation’s clinical-stage animal health product candidate. It is a vaccinia viral strain that selectively replicates in cancer cells to ultimately cause cell death (apoptosis). Who is Genelux Corporation? Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for human patients suffering from aggressive and/or difficult-to-treat solid tumor types. Learn more about Genelux and their technology at www.genelux.com. What is an oncolytic virus? An oncolytic virus is a virus that can infect and kill cancer [...]

jwiley2023-10-13T13:18:07-06:00October 13th, 2023|

ELIAS Animal Health Clinical Dataset Supports FDA Fast Track Designation for TVAX Biomedical

Exciting progress in the fight against cancer for both pets and humans On April 27, the US Food and Drug Administration (FDA) approved the application by our development partner, TVAX Biomedical, for Fast Track Designation for treatment of glioblastoma multiforme (GBM) with the immunotherapy technology ELIAS Animal Health is also using for treatment of osteosarcoma in dogs. Founded on the principle of translational medicine, ELIAS is especially pleased to have supported this major achievement. The efficacy and safety data from the previously completed canine osteosarcoma study conducted by ELIAS was an important component of the TVAX Fast Track application and we are pleased that the results of that study contributed to the FDA’s approval of the GBM Fast Track application. This is a significant accomplishment in that Fast Track Designation is not easily granted by the FDA and requires TVAX to provide evidence of its ability to successfully treat a [...]

jwiley2023-01-06T15:41:25-06:00May 5th, 2020|